Korsana Biosciences vs Xenon Pharmaceuticals
KRSA and XENE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRSA and XENE compare
Xenon Pharmaceuticals is the larger company, worth 25 times as much as Korsana Biosciences ($3.8B against $152M).
Korsana Biosciences grew revenue faster over the last twelve months (−12.6% versus −100% for Xenon Pharmaceuticals).
Xenon Pharmaceuticals scores higher on the StockData Score (7 against 6 for Korsana Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRSA | XENE |
|---|---|---|
| Size and price | ||
| Market cap | $152M | $3.8B |
| Share price | $32.50 | $38.78 |
| Change, 1 year | 241% | −4.9% |
| Change, 5 years | −90.5% | 41.3% |
| Beta (5Y) | 5.73 | 0.26 |
| Employees | 1 | 370 |
| StockData Score | ||
| Total score | 6 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 4 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 80.1× | – |
| P/B | 29.9× | 3.0× (better) |
| FCF yield | – | −9.0% |
| Fair value | $5.48 | – |
| Margin of safety | −493% | – |
| Growth | ||
| Revenue growth (TTM) | −12.6% (better) | −100% |
| Revenue growth, 5Y average | −2.0% (better) | −25.3% |
| Profitability | ||
| Operating margin | −359% | – |
| Net margin | −353% | – |
| Return on equity | −98.2% | −43.6% (better) |
| Return on invested capital | −116% (better) | −152% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.82 | 21.02 (better) |
| Altman Z-score | −9.25 | 40.35 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 15.1% | 104% |
| Held by insiders | – | 0.17% |
| Insider net buying, 12 months | – | −$20.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 7.6% |
Go deeper
- KRSA stock overview
- KRSA income statement
- KRSA valuation and score
- XENE stock overview
- XENE income statement
- XENE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.